Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2006 1
2007 1
2009 1
2011 1
2012 3
2013 1
2015 3
2016 1
2017 2
2019 3
2021 3
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Amyotrophic lateral sclerosis type 18"
Page 1
Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
James E, Ellis C, Brassington R, Sathasivam S, Young CA. James E, et al. Cochrane Database Syst Rev. 2022 May 20;5(5):CD006981. doi: 10.1002/14651858.CD006981.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593746 Free PMC article. Review.
BACKGROUND: Motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS), is a progressive neurodegenerative condition that may cause dysphagia, as well as limb weakness, dysarthria, emotional lability, and respiratory failure. ...The tria …
BACKGROUND: Motor neuron disease (MND), also known as amyotrophic lateral sclerosis (ALS), is a progressive neurodegene …
Causal role of high body mass index in multiple chronic diseases: a systematic review and meta-analysis of Mendelian randomization studies.
Larsson SC, Burgess S. Larsson SC, et al. BMC Med. 2021 Dec 15;19(1):320. doi: 10.1186/s12916-021-02188-x. BMC Med. 2021. PMID: 34906131 Free PMC article.
The aim of this study was to summarize the evidence from Mendelian randomization (MR) studies of the association between body mass index (BMI) and chronic diseases. ...In contrast, genetically predicted higher adult BMI was associated with a decreased risk of Dupuytren's d …
The aim of this study was to summarize the evidence from Mendelian randomization (MR) studies of the association between body mass in …
Nusinersen for adults with spinal muscular atrophy.
Arslan D, Inan B, Kilinc M, Bekircan-Kurt CE, Erdem-Ozdamar S, Tan E. Arslan D, et al. Neurol Sci. 2023 Jul;44(7):2393-2400. doi: 10.1007/s10072-023-06698-9. Epub 2023 Mar 1. Neurol Sci. 2023. PMID: 36854931
RESULTS: Median age at nusinersen initiation was 33.5 (20.0-60.0) years and 23 of SMA patients were male. Six (18.8%) patients had SMA type 2, and 26 (81.2%) had SMA type 3. Median follow-up period of patients under nusinersen treatment was 17 months (9-21). …
RESULTS: Median age at nusinersen initiation was 33.5 (20.0-60.0) years and 23 of SMA patients were male. Six (18.8%) patients had SM …
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial.
Thornton CA, Moxley RT 3rd, Eichinger K, Heatwole C, Mignon L, Arnold WD, Ashizawa T, Day JW, Dent G, Tanner MK, Duong T, Greene EP, Herbelin L, Johnson NE, King W, Kissel JT, Leung DG, Lott DJ, Norris DA, Pucillo EM, Schell W, Statland JM, Stinson N, Subramony SH, Xia S, Bishop KM, Bennett CF. Thornton CA, et al. Lancet Neurol. 2023 Mar;22(3):218-228. doi: 10.1016/S1474-4422(23)00001-7. Lancet Neurol. 2023. PMID: 36804094 Clinical Trial.
METHODS: In this dose-escalation phase 1/2a trial, adults aged 20-55 years with myotonic dystrophy type 1 were enrolled at seven tertiary referral centres in the USA and randomly assigned via an interactive web or phone response system to subcutaneous injecti …
METHODS: In this dose-escalation phase 1/2a trial, adults aged 20-55 years with myotonic dystrophy type 1 were enrolled at sev …
Is Innate Immunity and Inflammasomes Involved in Pathogenesis of Amyotrophic Lateral Sclerosis (ALS)?
Volpe CM, Nogueira-Machado JA. Volpe CM, et al. Recent Pat Endocr Metab Immune Drug Discov. 2015;9(1):40-5. doi: 10.2174/1872214809666150407111420. Recent Pat Endocr Metab Immune Drug Discov. 2015. PMID: 25845840 Review.
Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig's disease is an axonopathy with adultonset, progressive and irreversible degeneration of upper and lower motor neurons. Around 90% of ALS is considered as sporadic ALS (sALS) without apparent genetic cause whi …
Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig's disease is an axonopathy with adultonset, progressive and irreversi …
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
Baudin E, Goichot B, Berruti A, Hadoux J, Moalla S, Laboureau S, Nölting S, de la Fouchardière C, Kienitz T, Deutschbein T, Zovato S, Amar L, Haissaguerre M, Timmers H, Niccoli P, Faggiano A, Angokai M, Lamartina L, Luca F, Cosentini D, Hahner S, Beuschlein F, Attard M, Texier M, Fassnacht M; ENDOCAN-COMETE; ENSAT Networks. Baudin E, et al. Lancet. 2024 Mar 16;403(10431):1061-1070. doi: 10.1016/S0140-6736(23)02554-0. Epub 2024 Feb 22. Lancet. 2024. PMID: 38402886 Clinical Trial.
BACKGROUND: No randomised controlled trial has ever been done in patients with metastatic phaeochromocytomas and paragangliomas. ...Three deaths occurred in the sunitinib group: these deaths were due to respiratory insufficiency, amyotrophic lateral …
BACKGROUND: No randomised controlled trial has ever been done in patients with metastatic phaeochromocytomas and paraganglioma …
Health services utilization prior to amyotrophic lateral sclerosis diagnosis: A province-wide study of individuals treated with riluzole in Ontario, Canada.
Campitelli MA, Abrahao A, Maclagan LC, Fu L, Maxwell CJ, Swartz RH, Zinman L, Bronskill SE. Campitelli MA, et al. Muscle Nerve. 2021 Dec;64(6):691-700. doi: 10.1002/mus.27405. Epub 2021 Sep 28. Muscle Nerve. 2021. PMID: 34437716
INTRODUCTION/AIMS: Amyotrophic lateral sclerosis (ALS) symptoms mimic those of other conditions and often require multiple physician and healthcare contacts for investigation and accurate diagnosis. ...METHODS: This population-based cohort study used administ …
INTRODUCTION/AIMS: Amyotrophic lateral sclerosis (ALS) symptoms mimic those of other conditions and often require multi …
Enhanced Function and Overexpression of Metabotropic Glutamate Receptors 1 and 5 in the Spinal Cord of the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis during Disease Progression.
Bonifacino T, Rebosio C, Provenzano F, Torazza C, Balbi M, Milanese M, Raiteri L, Usai C, Fedele E, Bonanno G. Bonifacino T, et al. Int J Mol Sci. 2019 Sep 13;20(18):4552. doi: 10.3390/ijms20184552. Int J Mol Sci. 2019. PMID: 31540330 Free PMC article.
Glutamate (Glu)-mediated excitotoxicity is a major cause of amyotrophic lateral sclerosis (ALS) and our previous work highlighted that abnormal Glu release may represent a leading mechanism for excessive synaptic Glu. ...The mGluR1/5 agonist (S)-3,5-Dihydroxy …
Glutamate (Glu)-mediated excitotoxicity is a major cause of amyotrophic lateral sclerosis (ALS) and our previous work h …
Diaphragm pacing improves sleep in patients with amyotrophic lateral sclerosis.
Gonzalez-Bermejo J, Morélot-Panzini C, Salachas F, Redolfi S, Straus C, Becquemin MH, Arnulf I, Pradat PF, Bruneteau G, Ignagni AR, Diop M, Onders R, Nelson T, Menegaux F, Meininger V, Similowski T. Gonzalez-Bermejo J, et al. Amyotroph Lateral Scler. 2012 Jan;13(1):44-54. doi: 10.3109/17482968.2011.597862. Epub 2011 Oct 24. Amyotroph Lateral Scler. 2012. PMID: 22023158
In amyotrophic lateral sclerosis (ALS) patients, respiratory insufficiency is a major burden. Diaphragm conditioning by electrical stimulation could interfere with lung function decline by promoting the development of type 1 muscle fibres. We describe …
In amyotrophic lateral sclerosis (ALS) patients, respiratory insufficiency is a major burden. Diaphragm conditioning by …
Statistical analysis plan for the motor neuron disease systematic multi-arm adaptive randomised trial (MND-SMART).
Parker RA, Weir CJ, Pham TM, White IR, Stallard N, Parmar MKB, Swingler RJ, Dakin RS, Pal S, Chandran S. Parker RA, et al. Trials. 2023 Jan 16;24(1):29. doi: 10.1186/s13063-022-07007-z. Trials. 2023. PMID: 36647114 Free PMC article.
BACKGROUND: MND-SMART is a platform, multi-arm, multi-stage, multi-centre, randomised controlled trial recruiting people with motor neuron disease. Initially, the treatments memantine and trazodone will each be compared against placebo, but other investigational tre …
BACKGROUND: MND-SMART is a platform, multi-arm, multi-stage, multi-centre, randomised controlled trial recruiting people with …
23 results